T Skaali1, S D Fosså2, S Andersson3, M Cvancarova2, C W Langberg4, G Lehne5, A A Dahl2. 1. National Resource Center for Late Effects, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, and University of Oslo. Electronic address: Tone.Skaali@oslo-universitetssykehus.no. 2. National Resource Center for Late Effects, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, and University of Oslo. 3. Department of Neuropsychiatry and Psychosomatic Medicine, Oslo University Hospital, Rikshospitalet. 4. Department of Oncology, Oslo University Hospital, Ullevål Hospital. 5. Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
Abstract
BACKGROUND: Whether systemic chemotherapy has a negative effect on cognitive function in patients, concern oncologists. In testicular cancer patients (TCPs) treated with cisplatin-based chemotherapy, only few cross-sectional studies have addressed this concern. We prospectively studied neuropsychological functioning in TCPs. PATIENTS AND METHODS: In a consecutive sampling, 122 TCPs were examined at baseline (after orchidectomy, before any additional treatment) and then at follow-up at a median of 12 months after end of treatment. The examinations included a neuropsychological test battery, interview on background variables and questionnaires on mental distress, fatigue and neurotoxic symptoms. Changes in neuropsychological functioning from baseline to follow-up were compared between three treatments groups: no chemotherapy (N = 31), one cycle of chemotherapy (N = 38) and two or more cycles of chemotherapy (N = 53). Variables associated with a decline in neuropsychological test performance from baseline to follow-up were explored. RESULTS: No statistically significant differences in proportions of TCPs with a decline in neuropsychological test performance were observed between the three treatment groups. Decline in neuropsychological test performance was not associated with demographic variables, distress, fatigue or with chemotherapy. CONCLUSION: No negative effect of systemic chemotherapy on neuropsychological test performance in TCPs at 1-year follow-up was found in this study.
BACKGROUND: Whether systemic chemotherapy has a negative effect on cognitive function in patients, concern oncologists. In testicular cancerpatients (TCPs) treated with cisplatin-based chemotherapy, only few cross-sectional studies have addressed this concern. We prospectively studied neuropsychological functioning in TCPs. PATIENTS AND METHODS: In a consecutive sampling, 122 TCPs were examined at baseline (after orchidectomy, before any additional treatment) and then at follow-up at a median of 12 months after end of treatment. The examinations included a neuropsychological test battery, interview on background variables and questionnaires on mental distress, fatigue and neurotoxic symptoms. Changes in neuropsychological functioning from baseline to follow-up were compared between three treatments groups: no chemotherapy (N = 31), one cycle of chemotherapy (N = 38) and two or more cycles of chemotherapy (N = 53). Variables associated with a decline in neuropsychological test performance from baseline to follow-up were explored. RESULTS: No statistically significant differences in proportions of TCPs with a decline in neuropsychological test performance were observed between the three treatment groups. Decline in neuropsychological test performance was not associated with demographic variables, distress, fatigue or with chemotherapy. CONCLUSION: No negative effect of systemic chemotherapy on neuropsychological test performance in TCPs at 1-year follow-up was found in this study.
Authors: Jeffrey S Wefel; Damon J Vidrine; Salma K Marani; Richard J Swartz; Tracy L Veramonti; Christina A Meyers; Harald J Hoekstra; Josette E H M Hoekstra-Weebers; Ellen R Gritz Journal: Psychooncology Date: 2013-12-16 Impact factor: 3.894
Authors: Ali Amidi; Lisa M Wu; Anders Degn Pedersen; Mimi Mehlsen; Christina Gundgaard Pedersen; Philip Rossen; Mads Agerbæk; Robert Zachariae Journal: Support Care Cancer Date: 2015-02-26 Impact factor: 3.603
Authors: Cecilie R Buskbjerg; Robert Zachariae; Mads Agerbæk; Claus H Gravholt; Lene Haldbo-Classen; S M Hadi Hosseini; Ali Amidi Journal: Brain Imaging Behav Date: 2021-08-15 Impact factor: 3.978
Authors: Myrle M Stouten-Kemperman; Michiel B de Ruiter; Matthan W A Caan; Willem Boogerd; Martijn J Kerst; Liesbeth Reneman; Sanne B Schagen Journal: Hum Brain Mapp Date: 2015-08-25 Impact factor: 5.038
Authors: Karin Oechsle; Michael Hartmann; Anja Mehnert; Christoph Oing; Carsten Bokemeyer; Sigrun Vehling Journal: Support Care Cancer Date: 2015-11-18 Impact factor: 3.359